Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$50.13
At close: Jun 18, 4:00 PM EDT
$50.13
0.000.00%
Pre-Market: Jun 18, 4:00 PM EDT
Comments
Loading...
Bio-Techne Analyst Ratings and Price Targets | NASDAQ:TECH | Benzinga
Bio-Techne Corp has a consensus price target of $103.6 based on the ratings of 17 analysts. The high is $465 issued by Credit Suisse on August 25, 2022. The low is $59 issued by Wells Fargo on May 30, 2025. The 3 most-recent analyst ratings were released by Benchmark, Wells Fargo, and UBS on June 5, 2025, May 30, 2025, and May 9, 2025, respectively. With an average price target of $68 between Benchmark, Wells Fargo, and UBS, there's an implied 35.65% upside for Bio-Techne Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Wells Fargo
UBS
RBC Capital
Stifel
1calculated from analyst ratings
Analyst Ratings for Bio-Techne
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2025 | Buy Now | 49.61% | Benchmark | Robert Wasserman51% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2025 | Buy Now | 17.69% | Wells Fargo | Brandon Couillard69% | → $59 | Initiates | → Overweight | Get Alert |
| 05/09/2025 | Buy Now | 39.64% | UBS | Dan Leonard55% | $95 → $70 | Maintains | Buy | Get Alert |
| 05/08/2025 | Buy Now | 25.67% | RBC Capital | Conor McNamara37% | $72 → $63 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 49.61% | Benchmark | Robert Wasserman51% | $95 → $75 | Maintains | Buy | Get Alert |
| 05/08/2025 | Buy Now | 19.69% | Stifel | Daniel Arias78% | $75 → $60 | Maintains | Hold | Get Alert |
| 04/09/2025 | Buy Now | — | Keybanc | Paul Knight54% | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 03/18/2025 | Buy Now | 49.61% | Evercore ISI Group | Daniel Markowitz12% | → $75 | Initiates | → Outperform | Get Alert |
| 03/04/2025 | Buy Now | 39.64% | Citigroup | Patrick Donnelly80% | $80 → $70 | Maintains | Neutral | Get Alert |
| 02/19/2025 | Buy Now | 35.65% | Baird | Catherine Schulte66% | $88 → $68 | Downgrade | Outperform → Neutral | Get Alert |
| 02/06/2025 | Buy Now | 75.54% | Baird | Catherine Schulte66% | $86 → $88 | Maintains | Outperform | Get Alert |
| 02/06/2025 | Buy Now | 59.59% | RBC Capital | Conor McNamara37% | $79 → $80 | Maintains | Sector Perform | Get Alert |
| 02/06/2025 | Buy Now | 79.53% | Scotiabank | Sung Ji Nam46% | $88 → $90 | Maintains | Sector Outperform | Get Alert |
| 02/06/2025 | Buy Now | 79.53% | Keybanc | John Vinh73% | $80 → $90 | Maintains | Overweight | Get Alert |
| 10/31/2024 | Buy Now | 75.54% | Scotiabank | Sung Ji Nam46% | $83 → $88 | Maintains | Sector Outperform | Get Alert |
| 10/31/2024 | Buy Now | 67.56% | Baird | Catherine Schulte66% | $82 → $84 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 89.51% | Benchmark | Robert Wasserman51% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2024 | Buy Now | 39.64% | RBC Capital | Conor McNamara37% | $72 → $70 | Maintains | Sector Perform | Get Alert |
| 08/08/2024 | Buy Now | 63.57% | Baird | Catherine Schulte66% | $81 → $82 | Maintains | Outperform | Get Alert |
| 05/22/2024 | Buy Now | 69.56% | Citigroup | Patrick Donnelly80% | → $85 | Downgrade | Buy → Neutral | Get Alert |
| 05/02/2024 | Buy Now | 89.51% | Benchmark | Robert Wasserman51% | $95 → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 61.58% | Baird | Catherine Schulte66% | $73 → $81 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | 63.57% | Deutsche Bank | Justin Bowers46% | $85 → $82 | Maintains | Buy | Get Alert |
| 02/02/2024 | Buy Now | 29.66% | Stifel | Daniel Arias78% | → $65 | Downgrade | Buy → Hold | Get Alert |
| 02/02/2024 | Buy Now | 73.55% | Stephens & Co. | Jacob Johnson60% | $92 → $87 | Maintains | Overweight | Get Alert |
| 02/02/2024 | Buy Now | 49.61% | RBC Capital | Conor McNamara37% | $85 → $75 | Maintains | Sector Perform | Get Alert |
| 12/07/2023 | Buy Now | 59.59% | UBS | Dan Leonard55% | → $80 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | 29.66% | Stifel | Daniel Arias78% | $104 → $65 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 59.59% | Citigroup | Patrick Donnelly80% | $100 → $80 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 65.57% | RBC Capital | Conor McNamara37% | $85 → $83 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | 59.59% | Keybanc | Paul Knight54% | $115 → $80 | Maintains | Overweight | Get Alert |
| 09/12/2023 | Buy Now | 71.55% | RBC Capital | Conor McNamara37% | → $86 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/28/2023 | Buy Now | — | William Blair | Matt Larew25% | — | Initiates | → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 139.38% | Benchmark | Robert Wasserman51% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 99.48% | Stephens & Co. | Jacob Johnson60% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 79.53% | RBC Capital | Conor McNamara37% | $89 → $90 | Maintains | Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | 99.48% | Stephens & Co. | Jacob Johnson60% | → $100 | Reiterates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 99.48% | Baird | Catherine Schulte66% | $99 → $100 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | 75.54% | RBC Capital | Conor McNamara37% | $89 → $88 | Maintains | Sector Perform | Get Alert |
| 02/03/2023 | Buy Now | 139.38% | Benchmark | Robert Wasserman51% | → $120 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 119.43% | SVB Leerink | Puneet Souda56% | $125 → $110 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | 129.4% | Keybanc | Paul Knight54% | $125 → $115 | Maintains | Overweight | Get Alert |
| 01/10/2023 | Buy Now | 79.53% | Wells Fargo | Timothy Daley53% | → $90 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | 99.48% | Deutsche Bank | Justin Bowers46% | → $100 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 99.48% | Citigroup | Patrick Donnelly80% | $81.25 → $100 | Upgrade | Neutral → Buy | Get Alert |
| 12/07/2022 | Buy Now | 77.54% | RBC Capital | Conor McNamara37% | → $89 | Initiates | → Sector Perform | Get Alert |
| 12/05/2022 | Buy Now | 109.46% | Stephens & Co. | Jacob Johnson60% | $420 → $105 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 897.41% | SVB Leerink | Puneet Souda56% | $550 → $500 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 827.59% | Credit Suisse | Dan Leonard55% | → $465 | Initiates | → Outperform | Get Alert |
| 08/16/2022 | Buy Now | 618.13% | Wells Fargo | Timothy Daley53% | $370 → $360 | Maintains | Underweight | Get Alert |
| 08/05/2022 | Buy Now | 857.51% | Stephens & Co. | Jacob Johnson60% | $500 → $480 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Bio-Techne (TECH) stock?
The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Benchmark on June 5, 2025. The analyst firm set a price target for $75.00 expecting TECH to rise to within 12 months (a possible 49.61% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Techne (TECH)?
The latest analyst rating for Bio-Techne (NASDAQ:TECH) was provided by Benchmark, and Bio-Techne reiterated their buy rating.
When was the last upgrade for Bio-Techne (TECH)?
The last upgrade for Bio-Techne Corp happened on January 10, 2023 when Wells Fargo raised their price target to $90. Wells Fargo previously had an underweight for Bio-Techne Corp.
When was the last downgrade for Bio-Techne (TECH)?
The last downgrade for Bio-Techne Corp happened on April 9, 2025 when Keybanc changed their price target from N/A to N/A for Bio-Techne Corp.
When is the next analyst rating going to be posted or updated for Bio-Techne (TECH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Techne, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Techne was filed on June 5, 2025 so you should expect the next rating to be made available sometime around June 5, 2026.
Is the Analyst Rating Bio-Techne (TECH) correct?
While ratings are subjective and will change, the latest Bio-Techne (TECH) rating was a reiterated with a price target of $75.00 to $75.00. The current price Bio-Techne (TECH) is trading at is $50.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
